Business
Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds
Calgary, Alberta--(Newsfile Corp. - October 27, 2021) - Marvel Biosciences Corp. (TSXV: MRVL...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting CompoundsCalgary, Alberta--(Newsfile Corp. - October 27, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), is pleased to announce that the Company has initiated a new program whose goal is to identify and develop novel, safe agents that promote neuroplasticity without the liabilities of abuse potential or hallucinations that occur with psychedelics which include ketamine, LSD and tryptamine derivatives such as DMT and psilocybin. Marvel has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing. The compounds were administered for seven days, and preliminary evidence found multiple molecules with the same core structure capable of reducing depressive symptoms as measured in the widely accepted forced swim test. Early indications are extremely positive, with the swim test producing 2 positive indicators that exhibited strong potential for treatment. Key features of the first class of molecules that Marvel has developed are:fast acting orally availablewater soluble no evidence of hallucinatory activitysignificantly better (p<0.05) than fluoxetine (Prozac)\"Although early, this is an auspicious start for our new program that presents a compelling opportunity, as we further expand our product portfolio,\" commented Dr. Mark Williams, President and Chief Science Officer. \"We need to further characterize and expand upon the first set of hits we have identified, and we are also investigating molecules with very different structures to the known psychedelics to promote neuroplasticity as well. We are strong advocates for the use of psychedelic treatments to address mental health issues, yet it is critical that they are put through rigorous testing to ensure efficacy and safety for patients.\" \"This program is in addition to our current development program of our caffeine inspired lead compound asset MB-204 being developed for neurological conditions such as depression and anxiety, Alzheimer's disease (AD) and ADHD. MB-204 is in the manufacturing development phase and advancing well towards the clinic,\" stated Rod Matheson, Chief Execu...